$Gain Therapeutics (GANX.US)$ NEWS Gain Therapeutics Announc...
NEWS
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Positive results from the SAD part of the Phase 1 Clinical Trial of GT-02287.
GT-02287 was well tolerated with no serious adverse events.
Achieved appropriate plasma exposure levels after oral administration.
GT-02287 has the potential to slow or stop Parkinson's disease progression by treating the underlying cause.
Compelling preclinical data showed promising results in restoring motor function and reducing neurodegeneration biomarkers.
GT-02287 was well tolerated with no serious adverse events.
Achieved appropriate plasma exposure levels after oral administration.
GT-02287 has the potential to slow or stop Parkinson's disease progression by treating the underlying cause.
Compelling preclinical data showed promising results in restoring motor function and reducing neurodegeneration biomarkers.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
454Followers
65Following
2890Visitors
Follow